$CGTX News

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints

Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development

Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045

Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates

Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain

Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%

Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)

Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes

FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine

Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?